Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HPGDS | O60760 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 5/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14793107 | 1.00 | CYP2C9 (0.48) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL12147602 | 0.99 | CYP2C9 (0.47) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL15747168 | 0.95 | CYP2C9 (0.45) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL1317924 | 0.95 | CYP2C9 (0.45) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL1317926 | 0.95 | CYP2C9 (0.45) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL12107621 | 0.92 | CYP2C9 (0.47) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL14793256 | 0.92 | CYP2C9 (0.54) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL12107415 | 0.92 | CYP2C9 (0.47) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL14238590 | 0.91 | CYP2C9 (0.43) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 | |
| SCHEMBL14291668 | 0.90 | CYP2C9 (0.42) | CYP2C9KCNH2HPGDSCYP3A4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072523-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011079327-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072523-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | C1QBP, IRF3, IFNAR1 | CYP2C9 2610/4885KCNH2 2654/4885HPGDS 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.